Skip to content
Parnax Lab logo

Parnax Lab

PARNAXLAB NSE
₹104.47 +0.75 (+0.72%)
P/E
13.41
View as Markdown
MCP
Close 4 Nov 2026 ₹104.47 −23.23 −18.2% 1Y
Start ₹127.70

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
13.80%
Debt to Equity
0.87
EPS (TTM)
₹7.79
Book Value
₹82.83
Market Cap
—
P/E (TTM)
13.41
P/B
1.26
ROE
14.20%
Dividend Yield
0.00%
EBITDA
₹31.00 Cr
52W High
₹182.00
52W Low
₹90.00
Day Range
₹96.95 – ₹108.95
Volume
1,214

Peer Comparison

Healthcare › Pharmaceuticals

Parnax Lab peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Parnax Lab (this company)
₹104.4713.41₹117 Cr1.260.00%14.20%13.80%₹252 Cr₹9 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
60
Good
Cheap vs sector & own history 24% weight
Growth
80
Strong
Sales & profit trajectory 9% weight
Financial Health
26
Poor
Solvency, leverage, coverage 9% weight
Momentum
15
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBullish162
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
41.06
Neutral
MACD (12,26,9)
−3.63
Bullish
SMA (50)
118.12
Bearish
SMA (200)
131.32
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+13.37%
5Y+22.57%
3Y+14.02%
1Y+32.45%
TTM+31.92%

Net profit

Net profit growth by window
10Y+14.87%
5YZero base
3Y+10.06%
1Y0.00%
TTM−17.44%

Operating cash flow

Operating cash flow growth by window
10Y+10.31%
5Y+5.92%
3Y−27.51%
1Y−75.00%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−3.24 pp
5Y−0.27 pp
3Y−2.85 pp
1Y−3.52 pp
TTM−3.82 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹95.00 Cr
Mar 2018₹106 Cr
Mar 2019₹109 Cr
Mar 2020₹95.00 Cr
Mar 2021₹90.00 Cr
Mar 2022₹163 Cr
Mar 2023₹168 Cr
Mar 2024₹189 Cr
Mar 2025₹188 Cr
Mar 2026₹249 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹4.00 Cr
Mar 2018₹1.00 Cr
Mar 2019₹3.00 Cr
Mar 2020−₹3.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹8.00 Cr
Mar 2023₹9.00 Cr
Mar 2024₹10.00 Cr
Mar 2025₹12.00 Cr
Mar 2026₹12.00 Cr

Quarterly Results

₹ Cr
506128 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
48.74
42.61
50.99
46.37
50.12
48.36
40.22
49.04
53.38
62.6
62.94
69.63
56.8
Expenses
42.24
37.32
45.02
40.58
41.5
41.12
35.95
42.41
45.94
54.52
56.09
64.75
52.49
Operating Profit
6.5
5.29
5.97
5.79
8.62
7.24
4.27
6.63
7.44
8.08
6.85
4.88
4.31
OPM %
13.34%
12.41%
11.71%
12.49%
17.2%
14.97%
10.62%
13.52%
13.94%
12.91%
10.88%
7.01%
7.59%
Other Income
0.24
0.22
0.1
0.25
0.11
0.95
0.19
0.43
0.18
0.63
−0.17
1.76
0.15
Interest
1.16
1.43
1.35
1.41
1.5
1.38
1.23
1.28
1.22
1.4
1.47
1.61
1.64
Depreciation
1.6
1.74
1.78
1.84
1.83
1.94
1.79
1.83
1.94
2.1
1.96
2.04
2.22
PBT
3.98
2.34
2.94
2.79
5.4
4.87
1.44
3.95
4.46
5.21
3.25
2.99
0.6
Tax %
16.33%
20.09%
25.85%
19.35%
26.3%
29.77%
16.67%
26.08%
26.46%
30.33%
16.62%
27.09%
28.33%
Net Profit
3.33
1.87
2.18
2.24
3.99
3.42
1.21
2.93
3.28
3.62
2.71
2.19
0.43
EPS (₹)
2.89
1.63
1.9
1.95
3.47
2.97
1.05
2.54
2.85
3.16
2.36
1.9
0.37

Profit & Loss

₹ Cr
506128 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
103
71
95
106
109
95
90
163
168
189
188
249
252
Expenses
91
61
82
95
99
89
80
140
145
165
161
221
228
Operating Profit
12
10
13
10
10
6
10
23
23
24
27
27
24
OPM %
12%
14%
14%
10%
9%
7%
11%
14%
14%
12%
14%
11%
10%
Other Income
1
1
0
1
2
1
0
0
1
1
1
2
2
Interest
4
4
5
4
4
5
5
5
5
5
5
6
6
Depreciation
3
3
4
4
4
4
5
6
7
7
7
8
8
PBT
5
3
5
3
5
−2
0
12
12
12
16
16
12
Tax %
22%
28%
22%
65%
28%
48%
350%
33%
30%
20%
26%
26%
—
Net Profit
4
3
4
1
3
−3
0
8
9
10
12
12
9
EPS (₹)
5.01
2.95
4.33
1.23
3.88
−3.42
−0.42
8.4
7.51
8.37
10.03
10.26
7.79
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
506128 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
10
11
11
11
11
Reserves
17
19
23
24
27
24
24
38
51
60
72
84
Borrowings
41
42
39
37
42
51
59
69
55
81
70
83
Other Liabilities
17
10
15
18
17
23
15
36
28
38
37
50
Total Liabilities
83
79
86
87
95
107
106
153
145
190
190
228
Fixed Assets
36
38
47
44
51
58
60
72
77
89
88
115
CWIP
1
2
0
0
0
3
5
3
2
21
29
11
Investments
1
1
0
0
0
0
0
0
0
0
0
0
Other Assets
45
38
38
43
43
46
41
78
66
80
72
101
Total Assets
83
79
86
87
95
107
106
153
145
190
190
228

Cash Flow

₹ Cr
506128 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
3
16
13
9
9
6
9
21
16
32
8
Investing
−4
−6
−10
−5
−11
−13
−7
−16
−10
−32
−16
−16
Financing
6
1
−5
−7
1
5
0
12
−14
15
−16
8
Net Cash Flow
1
−2
0
1
−1
0
0
4
−3
−1
0
0
Free Cash Flow
−4
−3
5
8
−3
−4
0
−8
11
−16
16
−9
CFO/EBITDA
15
46
134
134
99
153
71
38
103
79
130
42

Ratios

506128 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
100
72
65
64
88
68
85
61
63
60
56
Inventory Days
38
64
50
45
52
76
80
73
79
94
87
82
Days Payable
51
30
48
45
44
74
46
81
53
74
72
73
Cash Conversion Cycle
71
134
74
64
72
90
102
77
86
83
75
65
Working Capital Days
16
7
−26
−8
0
−31
−66
−35
−19
−23
−24
−11
ROCE %
16%
11%
14%
11%
12%
3%
6%
17%
15%
13%
14%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Parnax Lab insights

61 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.30%
  • Public 22.71%
  • Others 4.99%

9.41% of promoter holding pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Parnax Lab

What does Parnax Lab Ltd do?
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations
Where is Parnax Lab Ltd (PARNAXLAB) listed?
Parnax Lab Ltd trades as PARNAXLAB on the NSE and under code 506128 on the BSE.
Which sector does Parnax Lab Ltd belong to?
Parnax Lab Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Parnax Lab Ltd?
Parnax Lab Ltd trades at a PE ratio of 13.41 as of 4 Nov 2026, on earnings per share of ₹7.79, against a book value of ₹82.83 per share.
What is the 52-week high and low of Parnax Lab Ltd?
Over the last 52 weeks Parnax Lab Ltd has traded between ₹90 and ₹182 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Parnax Lab Ltd?
Parnax Lab Ltd reported a return on equity of 14.20%. Its debt-to-equity ratio is 0.87.

Company Information

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations

Website naxparlab.com
Listed 17 Aug 2026
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506128.md for Parnax Lab Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month